ArticleNature genetics2024
In vivo CRISPR screens identify a dual function of MEN1 in regulating tumor-microenvironment interactions.
Abstract read
In one paragraph
Article in Nature genetics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- MEN1/menin deficiency suppresses hepatocellular carcinogenesis via disrupting mitophagy-mediated mitochondrial homeostasis.Autophagy · 2026Article
- Dual-line Genome-scale CRISPR Screening Enables Robust Target Gene Discovery.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- MEN1 Deficiency Drives Lung Cancer Progression via Activation of MMP10-Mediated Angiogenesis.Cancer science · 2026Article
- Cascade-responsive HA-decorated liposome/mesoporous silica nanoplatform co-delivering BMF-219 and 5-FU enhances gastric cancer chemotherapy through Menin- and p53-associated apoptotic signaling.Journal of experimental & clinical cancer research : CR · 2026Article
- Inhibition of SIRT7 Overcomes Radioresistance in Pancreatic Neuroendocrine Tumors by Reactivating MEN1 Expression.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- An integrated analysis of MEN1 reveals its associations with clinical outcomes, cellular pathways, and the immune microenvironment.World journal of surgical oncology · 2026Article
- Dual function of DOT1L suppresses tumor cell-intrinsic immunogenicity in hepatocellular carcinoma.Oncogene · 2026Article
- NSD2 inhibits the expression of PD-L1 via oxidative phosphorylation to control immune surveillance in hepatocellular carcinoma.Cell death & disease · 2026Article
- Two novel multiple endocrine neoplasia type 1 variants caused thymic neuroendocrine tumor: a case report.Hereditary cancer in clinical practice · 2026Article
- Therapeutic targeting of chromatin alterations in leukemia and solid tumors.International journal of cancer · 2026Review
- MEN1 Promotes Ferroptosis by Disrupting CD44 Alternative Splicing to Suppress Lung Cancer.Cancer research · 2026Article
- Case Report: Investigation and characterization of a multiple endocrine neoplasia type 1 case and its pedigree.Frontiers in endocrinology · 2026Article
- Exosome-derived Menin from cancer-associated fibroblasts promotes gastric cancer progression by activating the HSPA6/JNK/JunD pathway and inducing EMT.Journal of translational medicine · 2025Article
- Cancer Genomic Alterations and Microenvironmental Features Encode Synergistic Interactions with Disease Outcomes.Molecular cancer research : MCR · 2025Article
- Genome-wide CRISPR screen identifies Menin and SUZ12 as regulators of human developmental timing.Nature cell biology · 2025Article
- Unraveling the future of genomics: CRISPR, single-cell omics, and the applications in cancer and immunology.Frontiers in genome editing · 2025Review
- CRISPR/Cas9 technology in tumor research and drug development application progress and future prospects.Frontiers in pharmacology · 2025Review
- Cancer stem cells in personalized therapy: mechanisms, microenvironment crosstalk, and therapeutic vulnerabilities.Frontiers in cell and developmental biology · 2025Review
- Transforming cancer treatment: integrating patient-derived organoids and CRISPR screening for precision medicine.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
40 authors.
Peiran Su *Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.
Yin Liu *Department of Laboratory Medicine, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
Tianyi Chen *Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Yibo XuePrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Yong ZengPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.ORCID http://orcid.org/0000-0001-5719-1272
Guanghui ZhuPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.ORCID http://orcid.org/0000-0003-1495-4238
Sujun ChenPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.ORCID http://orcid.org/0000-0002-1941-3951
Mona TengDepartment of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.
Xinpei CiPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Mengdi GuoPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Michael Y HePrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.ORCID http://orcid.org/0000-0002-2235-2758
Jun HaoPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.ORCID http://orcid.org/0000-0002-8989-8771
Vivian ChuDepartment of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.
Wenxi XuPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Shiyan WangPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Parinaz MehdipourLudwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0002-4476-9925
Xin XuPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.ORCID http://orcid.org/0000-0003-4670-1243
Sajid A MarhonPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.ORCID http://orcid.org/0000-0002-1046-9852
Fraser SoaresPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.ORCID http://orcid.org/0000-0002-3977-7939
Nhu-An PhamPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.ORCID http://orcid.org/0000-0003-3063-0292
Bell Xi WuDepartment of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.
Peter Hyunwuk HerDepartment of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.
Shengrui FengDepartment of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.
Najd AlshamlanPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Maryam KhalilPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Rehna KrishnanPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Fangyou YuDepartment of Laboratory Medicine, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
Chang ChenDepartment of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.ORCID http://orcid.org/0000-0003-2841-1250
Francis BurrowsKura Oncology Inc, San Diego, CA, USA.
Razqallah HakemDepartment of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.
Mathieu LupienDepartment of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.
Shane HardingDepartment of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.
Benjamin H LokDepartment of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.
Catherine O'BrienDepartment of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.
Alejandro BerlinPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.ORCID http://orcid.org/0000-0002-1880-6905
Daniel D De CarvalhoDepartment of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.
David G BrooksPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Daniel SchramekDepartment of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.ORCID http://orcid.org/0000-0001-9977-2104
Ming-Sound TsaoDepartment of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada. Ming.Tsao@uhn.ca.ORCID http://orcid.org/0000-0002-9160-5405
Housheng Hansen HeDepartment of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada. hansenhe@uhnresearch.ca.ORCID http://orcid.org/0000-0003-2898-3363
Funding
Gouvernement du Canada | Canadian Institutes of Health Research (Instituts de Recherche en Santé du Canada) 142246, 152863,152864,159567,438793Gouvernement du Canada | Canadian Institutes of Health Research (Instituts de Recherche en Santé du Canada) FDN-148395National Natural Science Foundation of China (National Science Foundation of China) 31801111Princess Margaret Cancer Foundation (PMCF) 886012001223Terry Fox Research Institute (Institut de Recherche Terry Fox) 1090, 1124
Abstract
Functional genomic screens in two-dimensional cell culture models are limited in identifying therapeutic targets that influence the tumor microenvironment. By comparing targeted CRISPR-Cas9 screens in a two-dimensional culture with xenografts derived from the same cell line, we identified MEN1 as the top hit that confers differential dropout effects in vitro and in vivo. MEN1 knockout in multiple solid cancer types does not impact cell proliferation in vitro but significantly promotes or inhibits tumor growth in immunodeficient or immunocompetent mice, respectively. Mechanistically, MEN1 knockout redistributes MLL1 chromatin occupancy, increasing H3K4me3 at repetitive genomic regions, activating double-stranded RNA expression and increasing neutrophil and CD8
Indexed as
CD8-Positive T-LymphocytesCRISPR-Cas SystemsHistone-Lysine N-MethyltransferaseProto-Oncogene ProteinsTumor MicroenvironmentAnimalsCell Line, TumorCell ProliferationFemaleGene Expression Regulation, NeoplasticHumansMiceMyeloid-Lymphoid Leukemia ProteinNeoplasmsHistone-Lysine N-MethyltransferaseKMT2A protein, humanMEN1 protein, humanMyeloid-Lymphoid Leukemia ProteinProto-Oncogene Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.